Clinical and Imaging Trial of Uridine for Veterans With Suicidal Ideation

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind, placebo-controlled study of the investigational drug uridine as a treatment for suicidal ideation in veterans.

The investigators hypothesize that the administration of a naturally occurring dietary supplement, uridine, will rapidly reduce suicidal ideation in veterans. The purpose of this study is to determine whether 4 weeks of uridine supplementation is an effective treatment for suicidal ideation in veterans, when compared to a group taking a placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Perry Renshaw; VA Office of Research and Development
• Collaborator: VA Office of Research and Development

Criteria

Inclusion Criteria:

• Must be able to Provide Informed Consent.

• Must be a Veteran of the U.S. Armed Forces.

• Columbia-Suicide Severity Rating Scale Indicates Current Suicidal Ideation

• Beck Scale for Suicide Ideation Score > 3 (i.e. "Greater Than or Equal to 4").

• History of > 1 Suicide Attempt or Hospitalization to Prevent Suicide in Past 12 Months; or Functionally Impairing Suicidal Ideation Not Due to a DSM Axis II Diagnosis, in the Past 12 Months.

• Females and Males Ages 18-55 Inclusive.

• Willing and Able to Identify an Alternative Contact Person, e.g. Family Member, Friend or Neighbor.

Exclusion Criteria:

• Schizophrenia or Other Psychotic Disorder.

• Active Substance Use Disorder Requiring Stabilization (N.B. Does Not Include Nicotine).

• Unstable Medical Condition(s).

• Pregnancy or Breastfeeding.

• Contraindication to MRI (e.g. Ferrometallic Implant or Claustrophobic Anxiety).

• Concurrent Enrollment in Another Clinical Trial.

• Significant Risk of Protocol Non-Adherence (e.g. resides > 50 miles from the hospital, and has no automobile or alternate transportation).